628. Aggressive Lymphomas: Cellular Therapies: Poster II

Trial in progress Open label dose finding and dose expansion study to evaluate the safety expansion persistence and clinical activity of UCART20x22 in subjects with relapsed or refractory B cell non Hodgkin lymphoma B NHL nathali 01

First line consolidation with cemacabtagene ansegedleucel cema cel in patients with large B cell lymphoma LBCL and minimal residual disease MRD after response to standard therapy The pivotal randomized open-label Phase 2 ALPHA3 study

Risk of venous and arterial thromboembolic events following CAR T therapy in relapsed or refractory non Hodgkin lymphoma A propensity matched multicenter analysis

Assessing the utility of the charlson comorbidity index in predicting outcomes of CAR T therapy in patients with diffuse large B cell lymphoma

Propensity score matched analysis supports the survival benefits of combination chimeric antigen receptor T cell therapy with autologous transplantation in relapsed or refractory B cell non Hodgkin lymphoma Insights from a real world study in China

Long term cardiovascular outcomes in patients with lymphoma who had early post CAR T cardiovascular events A multi center international study

Cytomegalovirus CMV reactivation negatively impacts survival after CAR T cell therapy in lymphoma patients Results from the CART SIE study

Combining axicabtagene ciloleucel axi cel or relmacabtagene autoleucel relma cel with HDT ASCT in relapsed refractory large B cell lymphoma A single center experience

Modified beac as bridging lymphodepletion therapy followed by CAR T and autologous stem cell support in relapsed or refractory DLBCL patients Insights from safety and efficacy outcomes in 12 patients

Surrogate endpoints as prognostic factors for long term outcomes among patients receiving axicabtagene ciloleucel in frontline high risk large B cell lymphoma

Feasibility outcomes and challenges of CAR T cell therapy as advanced or earlier line of treatment for B cell non Hodgkin lymphomas A multicenter national study

Efficacy and safety of selinexor in combination with CD19 CD22 bispecific chimeric antigen receptor CAR T cell therapy for relapsed refractory diffuse large B cell lymphoma A single center retrospective real world study

Axi cel delivers similar outcomes regardless of ASCT eligibility in second line R R LBCL Combined data from ZUMA 7 and ALYCANTE

Safety and efficacy of CD19 CD22 CD20 multi targeted CAR T therapy in patients with refractory relapsed B cell non Hodgkin lymphoma

Long term follow up reveals sustained benefit of dual CD19 CD22 CAR T cell therapy alone or combined with autologous stem cell transplantation in TP53 altered relapsed refractory B cell non Hodgkin lymphoma

First line salvage therapies in relapsed refractory large B cell lymphoma after second or third line CD19 directed CAR T cell therapy

Lisocabtagene maraleucel liso cel versus standard of care SOC for second line relapsed or refractory large B cell lymphoma LBCL First Results from long term follow up of TRANSFORM

Targeting B and T cell lymphomas with anti CXCR5 CAR T cell therapy

CAR t cell therapy in TP53 mutated CNS lymphoma Overcoming a high risk genetic barrier

FOXO1 themis memory t cells underpin long term remission after cytokine armored CD19 CAR t therapy in refractory lymphoma

Impact of TP53 mutations on survival outcomes in the CAR t era of large b cell lymphoma

The first program for local CD19 CAR T production and treatment of lymphoma in the UAE  update median 1 year follow up and CART cell persistence